PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

A study to learn about safety and find out maximum tolerable dose of palbociclib given in
combination with chemotherapy (temozolomide with irinotecan or topotecan with
cyclophosphamide) in children, adolescents and young adults with recurrent or refractory
solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor
activity of palbociclib in combination with topotecan and cyclophosphamide in children,
adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn
about the efficacy of palbociclib in combination with irinotecan and temozolomide when
compared with irinotecan and temozolomide alone in the treatment of children, adolescents,
and young adults with recurrent or refractory Ewing sarcoma (EWS).

Inclusion:

1. Histologically confirmed relapsed or refractory solid tumor as follows:

- For dose escalation and dose determination parts: Histologically confirmed
relapsed or refractory solid tumor (including CNS tumors but not lymphomas).
Patients with Diffuse Intrinsic Pontine Glioma do not require histological only
radiographic confirmed relapse to enroll.

- For dose expansion and tumor specific cohorts: Histologically confirmed relapsed
or refractory solid tumor including but not limited to EWS, rhabdoid tumor,
rhabdomyosarcoma, neuroblastoma, and medulloblastoma. Patients with Diffuse
Intrinsic Pontine Glioma do not require histological only radiographic confirmed
relapse to enroll. EWS is not eligible for TOPO and CTX tumor-specific cohorts.

- For randomized Phase 2 part: Histologically confirmed Ewing sarcoma at diagnosis
or at relapse, with presence of EWSR1-ETS or FUS-ETS rearrangement.
Histopathology confirmation of both EWSR1-ETS or FUS-ETS rearrangement partners
is required OR availability of formalin fixed paraffin embedded (FFPE) tumor
tissue sample for central testing. Patient must have relapsed or have refractory
disease and at least evaluable disease in at least one site other than bone
marrow that can be followed by imaging.

2. Age ≥2 and <21 years at the time of study entry.

3. Lansky performance status ≥50% for patients ≤16 years of age, or Eastern Cooperative
Oncology Group (ECOG) 0, 1 or 2 for patients >16 years of age.

4. Adequate bone marrow function.

- Absolute neutrophil count ≥1000/mm3;

- Platelet count ≥75,000/mm3 (transfusion independent, no platelet transfusion in
past 7 days prior study entry);

- Hemoglobin ≥8.5 g/dL (transfusion allowed).

5. Adequate renal function: Serum creatinine level based on age/gender must within
protocol specified limits.

6. Adequate liver function, including:

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)

≤2.5 × upper limit of normal (ULN) or ≤5 × ULN for age, if attributable to
disease involvement of the liver;

- Total bilirubin ≤1.5 × ULN for age, unless the patient has documented Gilbert's
syndrome.Patients with documented Gilbert's syndrome are eligible if direct
bilirubin is within normal ranges (≤ULN).

7. Patients enrolled to Phase 1 portion of the study and tumor specific cohorts must have
measurable disease as defined by RECIST version 1.1 or modified RANO criteria for CNS
disease or at least evaluable disease by INRC for neuroblastoma.

The eligible patients with neuroblastoma must have at least one of the following at
the time of study entry:

- Measurable tumor by CT or MRI that is avid on MIBG scan or demonstrates increased
FDG uptake on PET scan;

- Avid lesion on MIBG scan with positive uptake at a minimum of one site;

- For disease that is not avid by MIBG-scan, at least one lesion that demonstrates
increased FDG uptake on PET scan AND viable neuroblastoma confirmed by current or
prior biopsy;

- bone marrow involvement with more than 5% neuroblastoma cells in at least one
sample from bilateral bone marrow biopsies;

- In non MIBG-avid refractory soft tissue disease that does not demonstrate
increased FDG uptake; lesion biopsy is required to document the presence of
viable neuroblastoma, unless patient has a new soft tissue lesion (radiographic
evidence of disease progression).

Patients with EWS enrolled to Phase 2 portion of the study are eligible with evaluable
disease (eg, bone only disease with no soft tissue component).

8. Recovered to CTCAE Grade ≤1, or to baseline, from any non-hematological acute
toxicities of prior surgery, chemotherapy, immunotherapy, radiotherapy,
differentiation therapy or biologic therapy, with the exception of alopecia.

9. Serum/urine pregnancy test (for all girls ≥8 years of age) negative at screening and
at the baseline visit.

Exclusion:

1. Phase 1 and tumor specific cohorts: For palbociclib with IRN and TMZ combination,
prior treatment with a CDK4/6 inhibitor or progression while on treatment with an
IRN-containing regimen that includes TMZ. Patients who have received the combination
of IRN and TMZ and did not progress while on these medications are eligible. For
patients enrolling in the palbociclib with TOPO and CTX combination, prior treatment
with a CDK4/6 inhibitor or progression while on treatment with a TOPO-containing
regimen that includes CTX. Patients who have received the combination of TOPO and CTX
and did not progress while on these medications are eligible. Phase 2 portion: prior
treatment with a CDK4/6 inhibitor or progression while on treatment with an
IRN-containing or TMZ-containing regimen. Patients who have received IRN and/or TMZ
and did not progress while on these medications are eligible.

2. Prior intolerability to IRN and/or TMZ plus/minus palbociclib with IRN and TMZ
combination and prior intolerability to TOPO and/or CTX for TOPO and CTX combination.
For patients enrolled in the UK, any contraindication for IRN and/or TMZ treatment, as
per the local SmPC.

3. Use of strong cytochrome P450 (CYP) 3A inhibitors or inducers within 12 days of study
entry. Patients who are receiving strong uridine diphosphate-glucuronosyl transferase
1A1 (UGT1A1) inhibitors within 12 days of Cycle 1 Day 1 (C1D1) are not eligible for
the palbociclib with IRN and TMZ combination. Patients who are receiving strong UGT1A1
inhibitors within 12 days of C1D1 are eligible for the palbociclib with TOPO and CTX
combination (See Section 5.7.1 for list of products.)

4. Systemic anti cancer therapy within 2 weeks prior to study entry and 6 weeks for
nitrosoureas.

5. Prior irradiation to >50% of the bone marrow (see Appendix 9).

6. Participation in other studies involving investigational drug(s) within 2 weeks or 5
half lives, whichever is longer, prior to study entry.

7. Major surgery within 4 weeks prior to study entry. Surgical biopsies or central line
placement are not considered major surgeries.

8. For IRN and TMZ with/without palbociclib combinations: known or suspected
hypersensitivity to palbociclib, dacarbazine, IRN and/or TMZ. For combination of
palbociclib with TOPO and CTX: known or suspected hypersensitivity to palbociclib,
TOPO and/or CTX.

9. Patients with known symptomatic brain tumors or brain metastases and require steroids,
unless they have been on a stable or on a decreasing steroid dose for >14 days.

10. Patients with previously diagnosed brain metastases are eligible if they have
completed their prior treatment and have recovered from the acute effects of radiation
therapy or surgery prior to study entry for these metastases for at least 14 days post
radiation and 4 weeks post-surgery and are neurologically stable.

11. Hereditary bone marrow failure disorder.

12. QTc >470 msec.

13. History of clinically significant or uncontrolled cardiac disease, including:

- History of or active congestive heart failure; if patient had congestive heart
failure resolve and >1 year from resolution, patient will be considered eligible;

- Clinically significant ventricular arrhythmia (such as ventricular tachycardia,
ventricular fibrillation or Torsades de Pointes);

- Diagnosed or suspected congenital or acquired prolonged QT syndrome;

- Need for medications known to prolong the QT interval;

- Uncorrected hypomagnesemia or hypokalemia because of potential effects on the QT
interval;

- Left ventricular ejection fraction <50% or shortening fraction <28%.

14. Recent or ongoing clinically significant gastrointestinal disorder that may interfere
with absorption of orally administered drugs (eg, gastrectomy).

15. Evidence of serious active or uncontrolled bacterial, fungal or viral infection or
known history of hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
infection or acquired immunodeficiency syndrome-related illness. Screening for viral
hepatitis and HIV is under discretion of investigator unless required by local
regulation.

16. Severe acute or chronic medical or laboratory test abnormality that may increase the
risk associated with study participation or investigational product administration or
may interfere with the interpretation of study results, and in the judgment of the
Investigator, would make the patient inappropriate for entry into this study.

17. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
patients who are Pfizer employees, including their family members, directly involved
in the conduct of the study.

18. Fertile male patients or female patients of childbearing potential who are unwilling
or unable to follow contraceptive requirements.

19. Pregnant or breastfeeding women.